Hormone cosmetics
This article was originally published in The Rose Sheet
Executive Summary
FDA withdraws advanced notice of proposed rulemaking for cosmetic products containing certain hormone ingredients effective Nov. 26, as it is no longer considered a viable candidate for further action, the agency reports in a 1Federal Register notice published last year and recently posted on dockets. Action is part of a move to reduce FDA's regulatory backlog. Agency received nine comments relating to the withdrawal of the hormone-containing cosmetics ANPR, some of which argued the move could call into question points raised in the proposed rule and change the marketing status of these products. FDA responds the withdrawal neither affirms nor rejects statements in the preamble, and as the proposed rule, published in 1993 permitting progesterone and pregnenolone in cosmetics in certain concentrations, was never finalized, its withdrawal does not change the marketing status of these products. Agency announced its intention to withdraw the proposed ANPR along with 83 other proposed actions in 2003 (2"The Rose Sheet" April 3, 2003, p. 10)...
You may also be interested in...
Hormone-Containing Cosmetics Rule Should Be Pursued – Advocacy Groups
Progesterone-containing topical cosmetics should be permitted on the market and FDA should pursue a final rule establishing such a policy, according to several alternative medicine and women's health advocacy groups
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.